More breast cancers found with combined digital screening

June 5, 2018, Radiological Society of North America

A combination of digital mammography and tomosynthesis detects 90 percent more breast cancers than digital mammography alone, according to a study appearing online in the journal Radiology.

Digital breast tomosynthesis (DBT) is an imaging technology that uses a series of low-dose mammographic exposures to provide a 3-D reconstruction of the breast. In studies comparing both technologies on the same women, DBT has proven to be more sensitive than digital in detecting cancers. Despite DBT's superior sensitivity, some groups caution that it could detect cancers that will never be clinically relevant—a phenomenon known as overdiagnosis.

To learn more about DBT's impact on sensitivity and recall rate, or the rate at which women are called back for additional based on suspicious results, researchers compared results between 9,777 women randomized to undergo digital mammography and DBT and 9,783 randomized to have digital mammography alone.

The combination of digital mammography and DBT detected 8.6 cancers per 1,000 cases, a rate almost twice that of the 4.5 per 1,000 detected by mammography alone. The recall rate was 3.5 percent in both groups. DBT alone detected 72 of 80 cancers found in the DBT and digital mammography group. The greater detection rate for combined digital mammography and DBT was notable for small and medium invasive cancers, but not for large ones.

"Tomosynthesis and digital mammography is much more sensitive than digital mammography," said the study's principal investigator, Pierpaolo Pattacini, M.D., radiologist and director of the Radiology Department at AUSL Reggio Emilia in Reggio Emilia, Italy. "The vast majority of the advantage is due to tomosynthesis alone."

While DBT's higher sensitivity would seem to make it a logical choice for screening programs, coauthor Paolo Giorgi Rossi, Ph.D., director of the Epidemiology Unit at AUSL Reggio Emilia said that more research is needed to weigh the benefits of improvements in prognosis and reductions in breast -related mortality from DBT against any undesired effects.

"If these small cancers would never become life-threatening, then we are increasing overdiagnosis and not impacting mortality," he said. "Thus, we need to have a measure of the impact of this higher detection rate on the incidence of advanced cancers and interval cancers in the following years."

The additional reading time DBT would require from breast imagers is another aspect of the technology that requires consideration, according to Dr. Giorgi Rossi.

"For publicly-funded screening programs, this increased reading time would be a big issue, destroying their sustainability," he said. "Implementing tomosynthesis in public screening programs would require rethinking protocols and reading technologies to reduce or eliminate the extra costs."

The new research represents a preliminary analysis from the Reggio Emilia Tomosynthesis trial (RETomo), a larger study in which researchers will be looking at interval cancers, or those detected between screening exams, and cumulative incidence of advanced cancers. To have more precise and reliable estimates of these outcomes, the researchers are promoting a network of ongoing trials on tomosynthesis with similar study design across Europe.

"Once we have this evidence, the consequences for screening could be even larger than a simple shift from to tomosynthesis," Dr. Giorgi Rossi said. "For example, it could be appropriate to adopt longer intervals between screenings."

Explore further: Tomosynthesis reduces breast cancer screening recall rate

More information: "Digital Mammography versus Digital Mammography Plus Tomosynthesis for Breast Cancer Screening: The Reggio Emilia Tomosynthesis Randomized Trial," Radiology, 2018.

Related Stories

Tomosynthesis reduces breast cancer screening recall rate

July 30, 2013
Digital tomosynthesis is an effective tool for reducing the recall rate in breast cancer screening, according to a new study published online in the journal Radiology.

Digital breast tomosynthesis cuts recall rates by 40 percent

May 3, 2012
Adding digital breast tomosynthesis to 2D mammography screening results in a 40% reduction in patient recall rates compared to routine screening mammography alone, a new study shows.

3-D mammography detects more invasive cancers and reduces call-back rates

June 24, 2014
Reporting in the June 25 issue of JAMA, researchers from Penn Medicine and other institutions found that 3D mammography—known as digital breast tomosynthesis— found significantly more invasive, or potentially lethal, ...

Tomosynthesis ups accuracy of digital mammography

January 4, 2013
(HealthDay)—Using a combination of tomosynthesis, which produces a three-dimensional reconstruction of the breast, with digital mammography increases radiologists' diagnostic accuracy and significantly lowers the number ...

Screening has had 'little impact' on falling breast cancer deaths in the Netherlands

December 5, 2017
Breast screening in the Netherlands seems to have had a marginal effect on breast cancer mortality over the past 24 years, suggests research in The BMJ today.

Screening mammography for women 40-49 detects more cancers compared with older age groups

March 13, 2018
When compared to the screening population ages 50 and over, screening mammography in women ages 40-49 detects 19.3% additional cancers at the expense of an overall 1.5% increase in callbacks and 0.1% in increased biopsies, ...

Recommended for you

Targeting the engine room of the cancer cell

June 18, 2018
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug ...

Researchers create novel combination as potential therapy for high-risk neuroblastoma

June 18, 2018
Researchers at VCU Massey Cancer Center in Richmond, Virginia, have identified a promising target to reverse the development of high-risk neuroblastoma and potentially inform the creation of novel combination therapies for ...

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...

Standard myelofibrosis drug can awaken 'dormant' lymphoma

June 18, 2018
Most patients with myelofibrosis, a rare chronic disorder of the haematopoietic cells of the bone marrow, benefit from drugs from the JAK2 inhibitor class: symptoms are relieved, survival extended and general quality-of-life ...

Genomics offers new treatment options for infants with range of soft tissue tumors

June 18, 2018
The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators. Whole genome sequencing of tumours revealed ...

Breast cancer researcher warns against online genetic tests

June 18, 2018
We have never been so fascinated by the secrets inside our cells.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.